PEDIATRICS Vol. 104 No. 2 August 1999, pp. 231-236

Safety of Withdrawing Inhaled Nitric Oxide Therapy in Persistent Pulmonary Hypertension of the Newborn

Received Sep 30, 1998; accepted Jan 26, 1999.

Dennis Davidson^*, , Elaine S. Barefield^{*, §}, John Kattwinkel^*, , Golde Dudell^{*, ¶}, Michael Damask^#, Richard Straube^#, Jared Rhines^#, Cheng-Tao Chang^#, and the I-NO/PPHN Study Group

From the From the ^* Departments of Pediatrics, the  Schneider Children's Hospital, Long Island Jewish Medical Center, The Long Island Campus for the Albert Einstein College of Medicine, New Hyde Park, New York; the ^§ University of Alabama, Birmingham, Alabama; the  University of Virginia, Charlottesville, Virginia; the ^¶ San Diego Children's Hospital, San Diego, California; and the ^# Ohmeda PPD, Liberty Corner, New Jersey.

Objective.  Because of case reports describing hypoxemia on withdrawal of inhaled nitric oxide (I-NO), we prospectively examined this safety issue in newborns with persistent pulmonary hypertension who were classified as treatment successes or failures during a course of I-NO therapy.

Methods.  Randomized, placebo-controlled, double-masked, dose-response clinical trial at 25 tertiary centers from April 1994 to June 1996. Change in oxygenation and outcome (death and/or extracorporeal membrane oxygenation) during or immediately after withdrawing I-NO were the principal endpoints. Patients (n = 155) were term infants, <3 days old at study entry with echocardiographic evidence of persistent pulmonary hypertension of the newborn. Exclusion criteria included previous surfactant treatment, high-frequency ventilation, or lung hypoplasia. Withdrawal from treatment gas (0, 5, 20, or 80 ppm) started once treatment success or failure criteria were met. Withdrawal of treatment gas occurred at 20% decrements at <4 hours between steps.

Results.  The patient profile was similar for placebo and I-NO groups. Treatment started at an oxygenation index (OI) of 25 ± 10 (mean ± SD) at 26 ± 18 hours after birth. For infants classified as treatment successes (mean duration of therapy = 88 hours, OI <10), decreases in the arterial partial pressure of oxygen (PaO₂) were observed only at the final step of withdrawal. On cessation from 1, 4, and 16 ppm, patients receiving I-NO demonstrated a dose-related reduction in PaO₂ (11 ± 23, 28 ± 24, and 50 ± 48 mm Hg, respectively). For infants classified as treatment failures (mean duration of therapy = 10 hours), no change in OI occurred for the placebo group (13 ± 36%, OI of 31 ± 11 after the withdrawal process); however a 42 ± 101% increase in OI to 46 ± 21 occurred for the pooled nitric oxide doses. One death was possibly related to withdrawal of I-NO.

Conclusion.  For infants classified as treatment successes, a dose response between the I-NO dose and decrease in PaO₂ after discontinuing I-NO was found. A reduction in I-NO to 1 ppm before discontinuation of the drug seems to minimize the decrease in PaO₂ seen. For infants failing treatment, discontinuation of I-NO could pose a life-threatening reduction in oxygenation should extracorporeal membrane oxygenation not be readily available or I-NO cannot be continued on transport.  Key words:  inhaled nitric oxide, persistent pulmonary hypertension of the newborn, extracorporeal membrane oxygenation, neonatal transport.

CiteULike    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				P. Namachivayam, U. Theilen, W. W. Butt, S. M. Cooper, D. J. Penny, and L. S. Shekerdemian Sildenafil Prevents Rebound Pulmonary Hypertension after Withdrawal of Nitric Oxide in Children Am. J. Respir. Crit. Care Med., November 1, 2006; 174(9): 1042 - 1047. [Abstract] [Full Text] [PDF]

				L. Chen, H. He, E. F. Mondejar, and G. Hedenstierna Cyclooxygenase inhibitor blocks rebound response after NO inhalation in an endotoxin model Am J Physiol Heart Circ Physiol, January 1, 2003; 284(1): H290 - H298. [Abstract] [Full Text] [PDF]

				N. N. Finer, J. W. Sun, W. Rich, E. Knodel, and K. J. Barrington Randomized, Prospective Study of Low-Dose Versus High-Dose Inhaled Nitric Oxide in the Neonate With Hypoxic Respiratory Failure Pediatrics, October 1, 2001; 108(4): 949 - 955. [Abstract] [Full Text] [PDF]

				L. Chen, H. He, E. F. Mondejar, F. Freden, P. Wiklund, K. Alving, and G. Hedenstierna Endothelin-1 and nitric oxide synthase in short rebound reaction to short exposure to inhaled nitric oxide Am J Physiol Heart Circ Physiol, July 1, 2001; 281(1): H124 - H131. [Abstract] [Full Text] [PDF]

				B. Weinberger, D. L. Laskin, D. E. Heck, and J. D. Laskin The Toxicology of Inhaled Nitric Oxide Toxicol. Sci., January 1, 2001; 59(1): 5 - 16. [Abstract] [Full Text] [PDF]

				S. R. Hintz, D. M. Suttner, A. M. Sheehan, W. D. Rhine, and K. P. Van Meurs Decreased Use of Neonatal Extracorporeal Membrane Oxygenation (ECMO): How New Treatment Modalities Have Affected ECMO Utilization Pediatrics, December 1, 2000; 106(6): 1339 - 1343. [Abstract] [Full Text]

				Committee on Fetus and Newborn Use of Inhaled Nitric Oxide Pediatrics, August 1, 2000; 106(2): 344 - 345. [Abstract] [Full Text]

				R. H. Clark How Do We Safely Use Inhaled Nitric Oxide? Pediatrics, August 1, 1999; 104(2): 296 - 296. [Full Text]